SynthesisThe British journal of surgery2024
Predictive value of pretreatment circulating inflammatory response markers in the neoadjuvant treatment of breast cancer: meta-analysis.
Synthesis in The British journal of surgery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Pathological complete response and prognostic predictive factors of neoadjuvant chemoimmunotherapy in early stage triple-negative breast cancer.Frontiers in immunology · 2025Trial
- Remnant cholesterol inflammatory index for predicting pathological complete response to neoadjuvant therapy in breast cancer: A multicenter external validation study.Breast (Edinburgh, Scotland) · 2026Article
- Predictive Value of the Inflammatory Burden Index for Pathological Complete Response in HER2-Positive and Triple-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy: A Comparative Analysis with Conventional Inflammatory Indices.Journal of clinical medicine · 2026Article
- Association of Pretreatment Serum Albumin and Systemic Inflammatory Markers with Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer.Journal of clinical medicine · 2026Article
- Development and multicenter validation of an immunoinflammatory marker-MRI model for pathological complete response after neoadjuvant chemotherapy in invasive breast cancer.Translational cancer research · 2026Article
- Article
- Analysis of Neutrophil/Lymphocyte Ratio as a Potential Biomarker Stratified by Breast Cancer Histologic Subtype.Diagnostics (Basel, Switzerland) · 2026Article
- Exploratory evaluation of CA 15-3 × NLR score for predicting pathologic complete response in breast cancer patients undergoing neoadjuvant chemotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Predicting the Effectiveness of 2 Chemotherapy Regimens Applied to Breast Cancer Patients by Nutritional and Inflammatory Status.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- Associations between pretreatment composite inflammatory indices and pathological response to neoadjuvant therapy in breast cancer: a retrospective cohort study.Frontiers in oncology · 2026Article
- An integrated CSF-serum biomarker model for predicting clinical progression in Alzheimer's disease.Frontiers in aging neuroscience · 2026Article
- Axillary Pathological Complete Response After Neoadjuvant Therapy in cN1-2 Breast Cancer: An Internally Validated PET/CT-Integrated Nomogram.Current oncology (Toronto, Ont.) · 2025Article
- Monocyte-to-lymphocyte ratio as a predictive marker for breast cancer treatment outcomes: a narrative review.Annals of medicine and surgery (2012) · 2025Review
- Artificial intelligence in healthcare and medicine: clinical applications, therapeutic advances, and future perspectives.European journal of medical research · 2025Review
- Artificial Intelligence-Based Pathology to Assist Prediction of Neoadjuvant Therapy Responses for Breast Cancer.Cancer medicine · 2025Review
- Unveiling the predictive role of systemic inflammation marker in mortality outcomes: a nationwide analysis of cancer survivorship in the United States.Discover oncology · 2025Article
- Gene mutation in cancer patients with diabetes: a real-world retrospective cohort study.BMC cancer · 2025Article
- Author response to: Comment on: Predictive value of pretreatment circulating inflammatory response markers in the neoadjuvant treatment of breast cancer: meta-analysis.The British journal of surgery · 2024Article
- Unraveling the ecological landscape of mast cells in esophageal cancer through single-cell RNA sequencing.Frontiers in immunology · 2024Article
Corrections and comments
- Commented on by
Authors and funding
8 authors.
Funding
Abstract
backgroundSystemic inflammatory response markers have been found to have a prognostic role in several cancers, but their value in predicting the response to neoadjuvant chemotherapy in breast cancer is uncertain. A systematic review and meta-analysis of the literature was carried out to investigate this.
methodsA systematic search of electronic databases was conducted to identify studies that explored the predictive value of circulating systemic inflammatory response markers in patients with breast cancer before commencing neoadjuvant therapy. A meta-analysis was undertaken for each inflammatory marker where three or more studies reported pCR rates in relation to the inflammatory marker. Outcome data are reported as ORs and 95% confidence intervals.
resultsA total of 49 studies were included, of which 42 were suitable for meta-analysis. A lower pretreatment neutrophil-to-lymphocyte ratio was associated with an increased pCR rate (pooled OR 1.66 (95% c.i. 1.32 to 2.09); P < 0.001). A lower white cell count (OR 1.96 (95% c.i. 1.29 to 2.97); P = 0.002) and a lower monocyte count (OR 3.20 (95% c.i. 1.71 to 5.97); P < 0.001) were also associated with a pCR. A higher lymphocyte count was associated with an increased pCR rate (OR 0.44 (95% c.i. 0.30 to 0.64); P < 0.001).
conclusionThe present study found the pretreatment neutrophil-to-lymphocyte ratio, white cell count, lymphocyte count, and monocyte count of value in the prediction of a pCR in the neoadjuvant treatment of breast cancer. Further research is required to determine their value in specific breast cancer subtypes and to establish optimal cut-off values, before their adoption in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.